3 Undervalued Biotechnology & Medical Research Stocks for Thursday, August 29
Discover the top 3 undervalued Biotechnology & Medical Research stocks for Thursday, August 29 based on AAII’s Stock Grades.Eunice Kim
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Commentary & Analysis
7 Undervalued Biotechnology & Medical Research Stocks for Tuesday, May 07
Discover the top 7 undervalued Biotechnology & Medical Research stocks for Tuesday, May 07 based on AAII’s Stock Grades.Jack Gilleland
5 Undervalued Biotechnology & Medical Research Stocks for Thursday, June 15
Discover the top 5 undervalued Biotechnology & Medical Research stocks for Thursday, June 15 based on AAII’s Stock Grades.Jenna Brashear
Is Dermata Therapeutics Inc (DRMA) Stock a Good Investment?
Learn more about Dermata Therapeutics Inc's (DRMA) stock grades for Value, Momentum, Growth and Estimate Revisions and determine whether this Biotechnology & Medical Research stock meets your investment needs.Jenna Brashear
Financial Summary
| Share Statistics | DRMA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2.5 | $211.8 | 3% |
|
| Shares Out (Mil) | 5.1 | 55.4 | 14% |
|
| Institutional Ownership | 24.3% | 93.0% | 11% |
|
| Float (Mil) | 2.7 | 41.5 | 7% |
|
| Beta | na | 0.99 | na |
|
| Avg Daily Volume (000s) | 87 | 553 | 34% |
|
| Price Change (52-week) |
(80.1%) | 42.8% | 9% |
|
| Growth | DRMA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | (18.9%) | (10.3%) | 21% |
|
| EPS (5yr) | na | 15.8% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | DRMA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $41 | na |
|
| Net Income (TTM) (Mil) | ($10) | ($44) | 29% |
|
| EPS (TTM) | ($2.686) | ($1.500) | 12% |
|
| Operating Cash Flow (TTM) (Mil) | ($9) | ($35) | 21% |
|
| Net Cash Flow (TTM) (Mil) | na | $-0 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | ($2) | $147 | 3% |
|
| Valuation | DRMA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.79 | 2.01 | 19% |
|
| P/E | na | 17.9 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | DRMA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 54.1% | 67.9% | 66% |
|
| Net Margin | na | (50.6%) | na |
|
| ROA | (162.3%) | (47.4%) | 2% |
|
| ROE | (241.5%) | (53.1%) | 3% |
|
| Liabilities to Assets | 41.1% | 29.7% | 32% |
|
| F-Score | 1 | 3 | 1% |
|
Dermata Therapeutics, Inc. did not pass any screens on 11/13/2026.
